Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment.
Chimeric antigen receptor (CAR) modified T cells have shown early promise in hematological malignancies. However, in solid malignancies CAR T cells must overcome a distinct immunosuppressive microenvironment which may compromise their capacity to mediate antitumor activity.
Abramson Cancer Center; Department of Medicine; Division of Hematology-Oncology; University of Pennsylvania Perelman School of Medicine ; Philadelphia, PA USA.
Gregory L
GL
Beatty
Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania ; Philadelphia, PA USA.
Edmund K
EK
Moon
CAR, chimeric antigen receptor; Lag3, lymphocyte-activation gene 3; PD1, programmed cell death 1; PDL1, programmed death ligand 1; TIM3, T cell immunoglobulin domain and mucin domain 3; adoptive cell therapy; cancer; chimeric antigen receptor T cells; immune checkpoint molecules; tumor microenvironment